Wasatch Advisors Inc Esperion Therapeutics, Inc. Transaction History
Wasatch Advisors Inc
- $19.9 Billion
- Q4 2024
A detailed history of Wasatch Advisors Inc transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Wasatch Advisors Inc holds 24,482,258 shares of ESPR stock, worth $38.7 Million. This represents 0.27% of its overall portfolio holdings.
Number of Shares
24,482,258
Previous 23,346,013
4.87%
Holding current value
$38.7 Million
Previous $38.5 Million
39.82%
% of portfolio
0.27%
Previous 0.19%
Shares
31 transactions
Others Institutions Holding ESPR
# of Institutions
215Shares Held
129MCall Options Held
1.78MPut Options Held
1.27M-
Black Rock Inc. New York, NY14MShares$22.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$18.5 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$15.7 Million0.44% of portfolio
-
Morgan Stanley New York, NY6.31MShares$9.97 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY6.23MShares$9.84 Million2.25% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $105M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...